Etirinotecan pegol
id:
etirinotecan-pegol-239-11773310
title:
Etirinotecan pegol
text:
Etirinotecan pegol is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017. It works as a topoisomerase I inhibitor. Chemically, it consists of four units of irinotecan linked by carboxymethyl glycine and polyethylene glycol (PEG) chains to a central pentaerythritol ether, resulting in a much longer biological half-life than that of irinotecan. It is f
brand slug:
wiki
category slug:
encyclopedia
description:
Pharmaceutical drug
original url:
https://en.wikipedia.org/wiki/Etirinotecan_pegol
date created:
date modified:
2023-06-14T23:54:50Z
main entity:
{"identifier":"Q105759773","url":"https://www.wikidata.org/entity/Q105759773"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/27/Etirinotecan_pegol.svg","width":2574,"height":1284}
fields total:
13
integrity:
15